These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23722322)

  • 1. Reduction of the washout time between natalizumab and fingolimod.
    de Seze J; Ongagna JC; Collongues N; Zaenker C; Courtois S; Fleury M; Benoilid A; Chanson JB; Blanc F;
    Mult Scler; 2013 Aug; 19(9):1248. PubMed ID: 23722322
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
    Jander S; Turowski B; Kieseier BC; Hartung HP
    Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

  • 4. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: closing in on an oral treatment.
    Martin R
    Nature; 2010 Mar; 464(7287):360-2. PubMed ID: 20237554
    [No Abstract]   [Full Text] [Related]  

  • 6. Delayed fingolimod-associated asystole.
    Espinosa PS; Berger JR
    Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.
    Laroni A; Brogi D; Milesi V; Abate L; Uccelli A; Mancardi G
    Mult Scler; 2013 Aug; 19(9):1236-7. PubMed ID: 23184503
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash.
    Stangel M; Stüve O
    Nat Rev Neurol; 2014 Jun; 10(6):311-3. PubMed ID: 24840971
    [No Abstract]   [Full Text] [Related]  

  • 9. Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.
    Stüve O; Hemmer B
    Mult Scler; 2012 Nov; 18(11):1514-6. PubMed ID: 23100520
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
    Kappos L; Radue EW; Comi G; Montalban X; Butzkueven H; Wiendl H; Giovannoni G; Hartung HP; Derfuss T; Naegelin Y; Sprenger T; Mueller-Lenke N; Griffiths S; von Rosenstiel P; Gottschalk R; Zhang Y; Dahlke F; Tomic D;
    Neurology; 2015 Jul; 85(1):29-39. PubMed ID: 26024899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving to fingolimod from natalizumab in multiple sclerosis-reply.
    Cohen M; Lebrun C
    JAMA Neurol; 2014 Jul; 71(7):925. PubMed ID: 25023556
    [No Abstract]   [Full Text] [Related]  

  • 13. Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved.
    Bianco A; Rossini PM; Mirabella M
    JAMA Neurol; 2014 Jul; 71(7):924-5. PubMed ID: 25023553
    [No Abstract]   [Full Text] [Related]  

  • 14. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.
    Ghezzi A; Rocca MA; Baroncini D; Annovazzi P; Zaffaroni M; Minonzio G; Comi G; Filippi M
    J Neurol; 2013 Jan; 260(1):327-9. PubMed ID: 23161460
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Rinaldi F; Seppi D; Calabrese M; Perini P; Gallo P
    Mult Scler; 2012 Nov; 18(11):1640-3. PubMed ID: 23100526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
    Weissert R
    Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab to fingolimod: Questions answered, unanswered, and unasked.
    Stüve O; Bourdette D
    Neurology; 2015 Jul; 85(1):14-5. PubMed ID: 26024898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.